ReviewCancers2024

Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer.

Kennady K Bullock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.